Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01838512 · ClinicalTrials.gov registry record
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
A clinical trial of Multiple Myeloma, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 2,555
- Enrollment target
- 20
- Study locations
NCT01838512 is a study of Multiple Myeloma that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 2,555 participants, above the 541-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (372% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT01838512, a study of Multiple Myeloma, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 2,555 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Conditions Studied
Study Locations (20)
California
- Local Institution - 0023 - Anaheim
- Local Institution - Anaheim
- Local Institution - 0045 - Burbank
- Local Institution - Corona
- Local Institution - 0048 - Downey
- Local Institution - 0052 - Fountain Valley
- Local Institute - Los Angeles
- Local Institute - Santa Rosa
- Local Institution - 0051 - Santa Rosa
Florida
- Local Institution - Brooksville
- Local Institution - 0044 - Fort Lauderdale
- Local Institution - Jacksonville
Georgia
- Local Institute - Valdosta
- Local Institution - 0047 - Valdosta
Illinois
- Local Institution - Skokie
- Local Institution - 0041 - Springfield
Indiana
- Local Institution - 0058 - Anderson
- Local Institution - 0011 - Indianapolis
Alabama
- Local Institution - Birmingham
Arizona
- Local Institute - Goodyear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,555 participants |
| Start Date | 2012-06-13 |
| Est. Completion | 2030-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01838512
The ClinicalTrials.gov registry entry for NCT01838512 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,555 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 541-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (372% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT01838512 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01838512 about?
NCT01838512 is a clinical study titled "Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)". The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
What is the current status of trial NCT01838512?
This trial is currently active not recruiting. The enrollment target is 2,555 participants. The study started on 2012-06-13. Estimated completion is 2030-03-31.
What conditions does trial NCT01838512 study?
This clinical trial studies the following conditions: Multiple Myeloma.
Who is sponsoring clinical trial NCT01838512?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01838512 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.